RESUMEN
INTRODUCTION: After two-stage exchange due to prosthetic joint infection (PJI), the new prosthesis carries a high risk of reinfection (RePJI). There isn`t solid evidence regarding the antibiotic prophylaxis in 2nd-stage surgery. The objective of this study is to describe what antibiotic prophylaxis is used in this surgery and evaluate its impact on the risk of developing RePJI. METHODS: Retrospective multicenter case-control study in Spanish hospitals. The study included cases of PJI treated with two-stage exchange and subsequently developed a new infection. For each case, two controls were included, matched by prosthesis location, center, and year of surgery. The prophylaxis regimens were grouped based on their antibacterial spectrum, and we calculated the association between the type of regimen and the development of RePJI using conditional logistic regression, adjusted for possible confounding factors. RESULTS: We included 90 cases from 12 centers, which were compared with 172 controls. The most frequent causative microorganism was Staphylococcus epidermidis with 34 cases (37.8%). Staphylococci were responsible for 50 cases (55.6%), 32 of them (64%) methicillin-resistant. Gram-negative bacilli were involved in 30 cases (33.3%), the most common Pseudomonas aeruginosa. In total, 83 different antibiotic prophylaxis regimens were used in 2nd-stage surgery, the most frequent a single preoperative dose of cefazolin (48 occasions; 18.3%); however, it was most common a combination of a glycopeptide and a beta-lactam with activity against Pseudomonas spp (99 cases, 25.2%). In the adjusted analysis, regimens that included antibiotics with activity against methicillin-resistant staphylococci AND Pseudomonas spp were associated with a significantly lower risk of RePJI (adjusted OR = 0.24; 95% IC: 0.09-0.65). CONCLUSIONS: The lack of standardization in 2nd-satge surgery prophylaxis explains the wide diversity of regimens used in this procedure. The results suggest that antibiotic prophylaxis in this surgery should include an antibiotic with activity against methicillin-resistant staphylococci and Pseudomonas.
Asunto(s)
Antibacterianos , Profilaxis Antibiótica , Infecciones Relacionadas con Prótesis , Humanos , Profilaxis Antibiótica/métodos , Infecciones Relacionadas con Prótesis/prevención & control , Infecciones Relacionadas con Prótesis/microbiología , Estudios de Casos y Controles , Masculino , Femenino , Estudios Retrospectivos , Anciano , Antibacterianos/uso terapéutico , Persona de Mediana Edad , Anciano de 80 o más Años , España , Prótesis Articulares/efectos adversos , Prótesis Articulares/microbiologíaRESUMEN
Mycobacterium fortuitum is a rapidly growing nontuberculous mycobacterium mainly associated with skin, soft tissue and surgical site infections. We report an unusual outbreak of 6 cases of surgical site infection following spinal surgery. Patients received combined intravenous antibiotics, including amikacin, followed by an extended period of oral therapy with favorable clinical outcomes. No instrumentation replacement was performed in any case.